Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data

doi:10.3748/wjg.v22.i4.1684

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16813)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-8) series.

Item

Count

PDF

1469

WORD

463

HTML

11380

Figures (1-3)

265

Tables (1-8)

238

Sum=13815

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1352

Download

1646

Sum=2998

Jan 28, 2016 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (97)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 28, 2016; 22(4): 1684-1700
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1684

Table 1 Hepatitis C virus seroprevalence among healthy adult population

S. #	Year	Place	Method	Sample size			Seroprevalence (%)			Ref.
S. #	Year	Place	Method	Male	Female	Total	Male	Female	Total	Ref.
1	2009	Lahore	ELISA⁹	-	-	2000	-	-	6.5	[38]
2	2009	Larkana	ICT¹	353	97	450	7.37	4.12	6.66	[46]
3	2010	Swat	ICT²	290	300	590	6.2	11.3	8.81	[45]
4	2010	Mansehra	ICT²	-	-	400	-	-	7.0	[36]
5	2010	Thatta/Nausheroferoz	ICT³	-	-	303	-	-	25.1	[29]
6	2010	Karachi(peri-Urban)	EIA⁴	649	1348	1997	19	26	23.83	[28]
7	2010	Karachi	ICT⁹	351	153	504	2.8	5.23	3.17	[34]
8	2010		ELISA⁹							[41]
		Multan		625	-	625	9.6	-	9.6
		Lahore		1892	-	1892	9.4	-	9.4
		Faisalabad		2736	-	2736	8.8	-	8.8
		Gujranwala		16522	-	16522	7.3	-	7.3
		Gujrat		9770	-	9770	6.8	-	6.8
		Sargodha		1620	-	1620	6.7	-	6.7
		Rawalpindi		445	-	445	6.7	-	6.7
		Sialkot		24707	-	24707	6.2	-	6.2
		Bahawalpur		363	-	363	5.0	-	5.0
9	2010	Islamabad	ICT⁹	-	252	252	-	24.6	24.6	[40]
10	2010	Mansehra	ICT⁹	394	254	648	11.8	9.4	10.34	[44]
11	2010	National Survey	ICT³	24444	22599	47043	4.9	4.8	4.87	[21]
12	2011	Gujranwala	EIA⁵	1770	732	2502	2.6	1.68	2.32	[43]
13	2011	Karachi	CLIA⁶	-	-	32049	-	-	9.75	[35]
14	2012	Kech	EIA⁷	709	1291	2000	7.62	4.34	5.5	[26]
15	2012	Punjab	EIA⁷	14027	14027	-	3.13	-	3.13	[39]
16	2014	Mardan	ICT⁸	757	662	1419	13.6	9.52	11.7	[37]
17	2014	Peshawar	CMIA⁴	543	439	982	15.4	9.7	12.93	[42]

¹Nobis Labordiagnostica, Cluj-Napoca, Romania;

²Acon Laboratories, CA, United States;

³Bionike Inc. CA, United States;

⁴Abbott Diagnostics, IL, United States;

⁵DSI, srl. Saronno VA, Italy;

⁶Roche Diagnostics, CA, United States;

⁷DiaSorin International Inc., Saluggia, Italy;

⁸Accurate Diagnostic Labs, NJ, United States;

⁹Manufacturer not mentioned in cited reference. ELISA: Enzyme linked immunosorbent assay; CLIA: Chemiluminescence immunoassay; ICT: Immunochromatographic test; EIA: Enzyme immunoassay; CMIA: Chemiluminescent microparticle immunoassay.

Table 2 Seroprevalence of hepatitis C virus infection in blood donors

S. #	Year	Place	Method	Sample size	Seroprevalence (%)	Ref.
1	2009	Mirpurkhas	ELISA⁷	804	15.05	[25]
2	2010	Multan	ELISA¹	10000	4.90	[88]
3	2010	Peshawar	ELISA⁷	32042	1.57	[92]
4	2011	KPK/FATA	ELISA²	7148	1.89	[89]
5	2011	KPK/FATA	ELISA²	62251	2.60	[91]
6	2011	Karachi	-⁸	5717	1.90	[86]
7	2012	Karachi	ELISA³	5517	2.00	[83]
8	2012	Peshawar	ELISA²	127828	2.46	[84]
9	2012	Sargodha	ELISA³	100	12.00	[85]
10	2013	Karachi	MEIA/CLIA⁴	108598	2.61	[87]
11	2013	Quetta	ELISA²	356	20.8	[27]
12	2013	Lahore	ELISA⁵	245	15.00	[82]
13	2014	Karachi	CLIA⁶	42830	1.65	[90]

¹Labkit Chemelex, Barcelona, Spain;

²Biokit;

³General Biologicals Corporation, Taiwan;

⁴Abbott Diagnostics,

⁵DiaSorin;

⁶Ortho Clinical Diagnostics, NJ, United States;

⁷Manufacturer not mentioned in cited reference;

⁸Method not mentioned in cited reference. KPK: Khyber Pakhtunkhwa; FATA: Federally Administered Tribal Areas; ELISA: Enzyme linked immunosorbent assay; MEIA: Microparticle immunoassay; CLIA: Chemiluminescence immunoassay.

Table 3 Hepatitis C virus in patients with liver disease

S. #	Year	Place	Method	Sample size	Seroprevalence (%)				Ref.
Hepatocellular carcinoma
1	2009	Punjab/KPK	ELISA¹	145	76.5				[97]
2	2009	Pakistan	EIA²	82	79.2				[98]
3	2010	Karachi	-⁵	40	50				[94]
4	2013	Pakistan	ELISA⁴	645	48.5				[95]
5	2014	Hyderabad	ELISA⁴	188	66				[96]
Liver disease					AH	CH/CLD	Carrier	Cirrhosis
6	2009	Swat	ELISA⁴	110	-	-	-	63.6	[99]
7	2009	Pakistan	EIA²	107	-	62.6	-	24.3	[98]
8	2010	Karachi	-⁵	5153	7	72.9	51.7	59.4	[94]
Hepatic encephalopathy
9	2009	Hyderabad	-⁵	87	66.67				[100]
Suspected for viral hepatitis
10	2014	Islamabad	ELISA³	845	24.8				[101]

¹DRG Instruments, Germany;

²Abbott Diagnostics;

³Biokit;

⁴Manufacturer not mentioned in cited reference;

⁵Method not mentioned in cited reference. AH: Acute hepatitis; CH: Chronic hepatitis; CLD: Chronic liver disease; ELISA: Enzyme linked immunosorbent assay; EIA: Enzyme immunoassay; KPK: Khyber Pakhtunkhwa.

Table 4 Hepatitis C virus serofrequency in high risk population groups

S. #	Year	Place	Method	Sample size	Seroprevalence (%)	Ref.
Pregnant women
1	2009	Hazara	ELISA¹	500	8.6	[104]
2	2009	Swat	ICT⁶	5607	2.6	[105]
3	2009	Karachi	EIA²	5902	1.8	[106]
4	2010	Multan	ICT⁶	500	7.0	[107]
5	2011	Karachi	ELISA³	18000	5.79	[102]
6	2013	Hyderabad	ELISA²	3078	4.7	[103]
Multi-transfused population (including pediatric population)
7	2009	Islamabad	ELISA⁶	103	36.0	[108]
8	2010	Lahore	Questionnaire	408	1.5	[110]
9	2011	KPK	ICT⁴	40	15.0	[111]
10	2011	Karachi	ELISA³	173	51.4	[86]
11	2012	Karachi	ELISA⁵	160	13.0	[83]
12	2014	Rawalpindi	ELISA⁶	95	49.5	[109]
Intravenous drug users
13	2011	KPK	ICT⁴	42	14.28	[111]
14	2011	KPK	ICT⁴			[113]
		Peshawar		100	35.0
		Kohat		60	25.0
		Mardan		40	32.5

¹Ortho Clinical Diagnostics;

²Abbott Diagnostics;

³DiaSorin;

⁴Acon Laboratories, CA, United States;

⁵General Biologicals Corporation;

⁶Manufacturer not mentioned in cited reference. KPK: Khyber Pakhtunkhwa; ELISA: Enzyme linked immunosorbent assay; EIA: Enzyme immunoassay; ICT: Immunochromatographic test.

Table 5 Hepatitis C virus serofrequency in miscellaneous high risk population groups

S. #	Year	Place	Method	Sample Size	Seroprevalence (%)	Ref.
Health care workers
1	2008	Abbottabad	ELISA⁷	125	5.6	[116]
2	2011	Peshawar	ICT¹	824	4.1	[115]
Prisoners
3	2010	Sindh	ELISA²	7539	12.8	[117]
4	2010	Karachi	ELISA³	357	15.2	[118]
Dialysis patients
5	2011	KPK	ICT⁴	25	28.0	[111]
6	2011	Peshawar	ELISA¹	384	29.2	[119]
Homosexual community
7	2010	Sindh	ELISA⁵	396	23.5	[120]
Vertical transmission
8	2011	Karachi	ELISA⁶	129	3.9	[102]

¹Acurate Diagnostics;

²Medical Biological Services, Italy;

³Abbott Diagnostics;

⁴Acon Laboratories;

⁵Biokit;

⁶DiaSorin;

⁷Manufacturer not mentioned in cited reference. KPK: Khyber Pakhtunkhwa; ELISA: Enzyme linked immunosorbent assay; ICT: Immunochromatographic test.

Table 6 Hepatitis C virus seropositivity among patients other than those with liver disease

S. #	Year	Place	Method	Sample size	Seroprevalence (%)	Ref.
Urological patients
1	2010	Lahore	ELISA⁴	558	13.4	[130]
Major gynecological surgery
2	2009	Karachi	EIA¹	548	16.2	[106]
Surgery (eye/elective/major)
3	2010	Sukkur	ICT⁵	913	13.8	[126]
4	2011	KPK	ICT²	25	8.0	[111]
5	2013	Kharian	ELISA⁵	554	6.4	[122]
Dental surgery
6	2011	KPK	ICT²	35	14.28	[111]
Type II diabetes
7	2010	Multan	ELISA³	3000	30.2	[88]
Cataract patients
8	2012	Karachi	ELISA⁵	377	11.4	[127]
Dermatological disorders
9	2012	Karachi/Rawalpindi	ELISA⁵	355	9.01	[128]
Tuberculosis patients
10	2013	Rahim Yar Khan	ELISA⁴	110	9.1	[121]
Sexually transmitted infection patients
11	2014	Faisalabad	ELISA¹	39780	21.99	[124]
Seeking hospital care (Misc diseases/disease not defined)
12	2010	Bannu	ELISA⁵	25944	3.3	[125]
13	2011	Karachi	ELISA¹	2965	12.8	[123]
14	2011	Kotli (AJK)	ELISA⁵	9564	6.38	[129]

¹Abbott Diagnostics;

²Acon Laboratories;

³Labkit;

⁴Bio-tech Company Limited, United States;

⁵Manufacturer not mentioned in cited reference. KPK: Khyber Pakhtunkhwa; ELISA: Enzyme linked immunosorbent assay; EIA: Enzyme immunoassay; ICT: Immunochromatographic test.

Table 7 Prevalence of active hepatitis C virus infection in Pakistan

S. #	Year	Place	Sample size			Active HCV infection (%)			Ref.
S. #	Year	Place	Male	Female	Total	Male	Female	Total	Ref.
General population
1	2010	Swat	290	300	590	2.8	5.7	4.2	[45]
2	2010	Mansehra	300	100	400	4.0	2.0	3.5	[36]
3	2012	Rawalpindi	147	156	303	17.7	16.7	17.2	[135]
		Islamabad	75	125	200	5.3	3.2	4.0
4	2013	Lahore	1914	2332	4246	5.3	4.7	4.9	[134]
5	2014	Mardan	757	662	1419	11.5	5.1	8.5	[37]
Intravenous drug users
6	2011	KPK			42			14.3	[111]
7	2011	KPK			200			24.0	[113]
Dialysis patients
8	2011	KPK			25			28.0	[111]
9	2011	KPK			384			27.6	[119]
Blood donors
10	2011	KPK/FATA	-	-	7148	-	-	1.6	[89]
Health care workers
11	2011	KPK			824			2.8	[115]
Multi transfused population
12	2011	KPK			40			15.0	[111]
Patients undergoing major surgery
13	2011	KPK			25			8.0	[111]
Dental surgery patients
14	2011	KPK			35			14.3	[111]
Pregnant women
15	2011	Karachi			18000			-¹	[102]

¹Out of 18000 subjects studied, 1043 women tested positive for anti- hepatitis C virus (HCV) during screening; only 640 out of these 1043 agreed to undergo nucleic acid testing of which 510 tested positive for HCV-RNA. KPK: Khyber Pakhtunkhwa; FATA: Federally Administered Tribal Areas.

Table 8 Frequency distribution of hepatitis C virus genotypes in Pakistan

Frequency (%) of hepatitis C virus genotypes
1			2			3			4			5		6		Mixed	Untypable	Ref.
1a	1b	U	2a	2b	U	3a	3b	U	4a	4b	U	5a	U	6a	U
3.5	0.8	-	1	-	-	88.1	3	-	-	-	-	-	-	-	-	3.6	-	[142]
6.1	6	-	15.1	6.1	-	42.3	12.1	-	-	-	-	-	-	-	-	-	12.1	[45]
0.72	0.72					80.26	6									6.73	27.88	[151]
5.4			8.1			34.1	7									7.6	37.8	[154]
1.5	2.5		39	1		31	8										17	[17]
7.14			35.71			28.6					14.29						14.29	[113]
12.1	1.2	-	1.2	0.4	0.3¹	64.5	6.4	0.001¹	6.7	0.6	-	0.5	-	0.4	-	3.2	2.4	[156]
14.3	3.6	-	8.9	1.8	-	32.1	17.8		1.8							10.7	8.9	[119]
6.8	4.6		1.3			54.4	8.2									8.2	16.4	[152]
5.6	-	-	-	-	-	90.3	0.6	-	-	-	0.6	-	-	-	-	2.8	-	[141]
2.6	0.8	-	0.3	0.2	-	82.6	0.2	-	-	-	-	0.1	-	-	-	2.4	10.8	[150]
12.5	8.9		9.8	1.8		42.9	22.3										1.8	[149]
7.4	5.8	-	13.2	6.6	-	26.4	16.5	-	-	-	2.5	-	-	-	-	4.1	17.4	[37]
10	3.6	-	-	-	-	56.4	15	-	-	-	1.4	-	-	-	-	7.1	6.4	[143]
1.3	0.7	-	-	-	-	82.1	13.9	-	-	-	-	-	-	-	-	2	-	[146]
1	-	-	12	-	-	38.2	21	-	-	-	-	-	-	-	-	7.3	21	[148]
8.8	3	-	6.5	1	-	45.5	16	-	0.8	-	-	-	-	-	-	16	2.2	[145]
5.3	5.1	1¹	24.9	6.1	-	39.4	6.3	-	2.4			2.4		2		-	5.7	[18]
2.9	1.5	-	-	-	1.2	70.3	5.5	-	-	-	-	-	0.9	-	-	2.6	15.1	[157]
3.3	0.8	0.2¹	2.1	0.2	0.02¹	61	8.9	0.24¹	-	-	0.5	0.1		0.1		4.7	17.8	[153]
23.6	-	-	-	-	-	55.9	3.2	-	12.5	1.2	-	-	-	-	-	1.2	2.5	[155]
4.3	-	-	-	-	-	73.9	13	-	-	-	-	-	-	-	-	4.3	4.3	[115]
0.9	0.9	-	7.4	0.9	-	66.1	2.6	-	-	-	-	-	-	-	-	2.2	18.8	[144]
-	-	-	1.1	2.2	-	86.8	2.2	-	-	-	-	-	-	-	-	-	7.7	[149]
7.1	-	-	-	-	-	50	10.7	-	-	-	-	-	-	-	-	-	32.1	[140]
0.5	1.5	-	10.3	1.2	-	68.3	2.6	-	-	-	-	-	-	-	-	-	15.6	[158]

¹Subtype C. U: Undefined subtype.

Citation: Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol 2016; 22(4): 1684-1700
URL: https://www.wjgnet.com/1007-9327/full/v22/i4/1684.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i4.1684